Tracy Foster
Family · Beaumont, TXNPI 1689012965
Payments from drug & device makers
Across 298 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Novartis$669
- Merck$479
- Johnson & Johnson$459
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$416
- Boehringer Ingelheim$237
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,038100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 71 | $1,103 |
| Novartis | 55 | $669 |
| Merck | 30 | $479 |
| Johnson & Johnson | 31 | $459 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $416 |
| Boehringer Ingelheim | 11 | $237 |
| Abbott | 5 | $198 |
| Lexicon Pharmaceuticals, Inc. | 9 | $194 |
| Pfizer | 10 | $167 |
| Amarin Pharma, Inc. | 9 | $149 |
| Amgen | 9 | $140 |
| Novo Nordisk | 3 | $126 |
| Cleerly, Inc. | 1 | $94 |
| Inspire Medical Systems, Inc. | 2 | $78 |
| Esperion Therapeutics, Inc. | 4 | $71 |
| E.r. Squibb & Sons, L.L.C. | 5 | $68 |
| Tactile Systems Technology Inc | 4 | $59 |
| Kestra Medical Technology Services, Inc. | 1 | $42 |
| Endologix LLC | 1 | $35 |
| Preventice Services, LLC | 3 | $33 |
| Medtronic | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| AstraZeneca | 2 | $26 |
| Elutia, Inc. | 2 | $26 |
| Irhythm Technologies, Inc. | 1 | $25 |
| Heartflow, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,049 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 414 | $328,933 |
| EntrestoSacubitril/Valsartan | 198 | $178,670 |
| XareltoRivaroxaban | 151 | $140,842 |
| JardianceEmpagliflozin | 164 | $106,000 |
| Repatha SureclickEvolocumab | 90 | $57,631 |
| OzempicSemaglutide | 23 | $29,756 |
| MultaqDronedarone Hcl | 17 | $20,277 |
| VascepaIcosapent Ethyl | 27 | $12,244 |
| Praluent PenAlirocumab | 19 | $10,971 |
| CorlanorIvabradine Hcl | 13 | $8,885 |
| Rosuvastatin Calcium | 370 | $7,943 |
| Metoprolol Succinate | 361 | $5,640 |
| Nifedipine ErNifedipine | 198 | $4,475 |
| BrilintaTicagrelor | 11 | $4,448 |
| Carvedilol | 514 | $3,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $167 | $328,933414 claims |
| NovartisEntresto | $669 | $178,670198 claims |
| Johnson & JohnsonXarelto | $459 | $140,842151 claims |
| Boehringer IngelheimJardiance | $237 | $106,000164 claims |
| Novo NordiskOzempic | $126 | $29,75623 claims |
| Sanofi-aventis U.S. LLCMultaq | $22 | $20,27717 claims |
| AmgenCorlanor | $140 | $8,88513 claims |
| AstraZenecaBrilinta | $26 | $4,44811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Beaumont
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.